Tech Company Financing Transactions
Pyxis Oncology Funding Round
Pyxis Oncology closed a $152 million Series B venture capital round on 3/31/2021. Investors included Arix Bioscience, RTW Investments and Acuta Capital.
Transaction Overview
Company Name
Announced On
3/31/2021
Transaction Type
Venture Equity
Amount
$152,000,000
Round
Series B
Investors
Arix Bioscience (Lead Investor)
RTW Investments (Lead Investor)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
35 Cambridgepark Dr.
Cambridge, MA 02140
USA
Cambridge, MA 02140
USA
Phone
Website
Email Address
Overview
Pyxis Oncology has assembled a differentiated portfolio of potent biologics, including antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies with the potential to further improve the outcome for patients with cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
David Steinberg
Chief Executive Officer
Lara Sullivan
Chief Financial Officer
Robert Crane
Chief Operating Officer
Ritu Shah
Chief Scientific Officer
Ronald Herbst
Chief Technical Officer
Steve Monks
VP - Bus. Development
James Mutamba
Browse more venture capital transactions:
Prev: 3/31/2021: Lifelink Systems venture capital transaction
Next: 3/31/2021: Omega Therapeutics venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC investment data records on this site are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs